Coronavirus Pandemic

Transplant Clinical Trials

Current Kidney Clinical Trials:

  • My Gain Study: A 4-week, multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal safety and tolerability of myfortic® and MMF (CellCept®) when administered in combination with calcineurin inhibitors in renal transplant recipients experiencing gastrointestinal Intolerance. Study #CERL080AUS51
  • Impact Study: A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients. Study #NT18435

Current Liver Clinical Trials:

  • A prospective, open-label, multi-center, randomized trial of the efficacy and safety of a long term calcineurin inhibitor free maintenance regimen with mycophenolate mofetil and sirolimus in recipients of an orthotopic liver transplant.

Projects in Development:

  • Phase IIa/IIb Trial A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus in combination with myfortic®, Simulect® and corticosteroids in de novo adult renal transplant recipients. AEB071 CAEB071A2207 MORE Registry: A Phase IV, multi-center, prospective, observational study of the safety, effectiveness and tolerability of immunosuppressant regimens to treat renal transplant patients in routine clinical practice.